-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JCHKAMaMiWdESARNKiKtJJwMARgorJGpTytA/lt9o/lBkHLRmLQato7KdM3QQbWU
 0f1WG75y+86nfntlAKm8iA==

<SEC-DOCUMENT>0001075880-07-000023.txt : 20070504
<SEC-HEADER>0001075880-07-000023.hdr.sgml : 20070504
<ACCEPTANCE-DATETIME>20070504092910
ACCESSION NUMBER:		0001075880-07-000023
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070504
FILED AS OF DATE:		20070504
DATE AS OF CHANGE:		20070504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		07817964

	BUSINESS ADDRESS:	
		STREET 1:		140 WICKS RD
		STREET 2:		NORTH RYDE
		CITY:			NEW SOUTH WALES 2113
		STATE:			C3
		ZIP:			2113
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		107 NORTH RYDE
		CITY:			SYDNEY
		STATE:			C3
		ZIP:			1670
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k20070504.htm
<DESCRIPTION>FORM 6K 2007-05-04
<TEXT>
<html>
  <head>
    <title>
      Form 6K 2007-05-04
</title>
<!-- Licensed to: 97ut5rw-->
<!-- Document Created using EDGARizer HTML 3.0.4.0 -->
<!-- Copyright 2006 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff"><br>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>______________________________________________</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>REPORT
      OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
      THE</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      EXCHANGE ACT OF 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">For
      the
      month of May, 2007</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Commission
      File Number </font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 36pt; FONT-FAMILY: Times New Roman"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">140
      Wicks
      Road, North Ryde, NSW, Australia</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive office)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">___________________________________</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover of Form 20-F or Form 40-F. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Form
      20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Wingdings"><strong>x</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Form
      40-F
</font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Wingdings"><strong>o</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(l):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
      Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
      6-K if submitted solely to provide an attached annual report to security
      holders.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule lO1(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Note:
      Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form
      6-K
      if submitted to furnish a report or other document that the registrant foreign
      private issuer must furnish and make public under the laws of the jurisdiction
      in which the registrant is incorporated, domiciled or legally organized (the
      registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
      which the registrant&#8217;s securities are traded, as long as the report or other
      document is not a press release, is not required to be and has not been
      distributed to the registrant&#8217;s security holders, and, if discussing a material
      event, has already been the subject of a Form 6-K submission or other Commission
      filing on EDGAR.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes </font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Wingdings"><strong>o</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">No
      </font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Wingdings"><strong>x</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant
      has
      duly caused this report to be signed on its behalf </strong></font><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">by
      the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>Novogen
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>/s/
      Ron Erratt</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Ronald
      Lea Erratt</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Company
      Secretary</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>Date
      4 May, 2007</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><img src="novogen5.jpg" alt=""></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>ASX
      &amp; MEDIA RELEASE</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><strong>4
      MAY, 2007</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">NOVOGEN
        CONSUMER PRODUCTS FACILITY</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Following
        an extensive review of capacity, quality, and technical capabilities ASX
        listed
        pharmaceutical company, Novogen Limited advises it will source its worldwide
        requirements for isoflavones for use in the production of its consumer products
        Promensil and Trinovin from a red clover extraction facility in
        Switzerland.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">With
        patents surrounding Promensil and Trinovin having been granted in most major
        territories there is no longer a need for Novogen to have in-house isoflavone
        extraction facilities in order to protect its Intellectual property in this
        area. Accordingly, it is now open to the Company to source its red clover
        isoflavones from the most economic and technically advanced extraction
        facilities which combine the high product standards that Novogen
        requires.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">As
        a
        result of the new supply arrangements, the existing Wyong isoflavone extraction
        facility will be decommissioned and the property sold. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">The
        Wyong
        extraction facility was opened 10 years ago and was the first red clover
        extraction unit in the world. By owning and operating its own facility Novogen
        ensured that its intellectual property was secure, and the quality of the
        active
        ingredient was of the highest standards. In the intervening decade however
        the
        product and manufacturing patents covering Promensil and Trinovin have been
        proceeding to grant through the patent offices around the world. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Christopher
        Naughton, CEO of Novogen said &#8220; We are dedicated to providing quality products
        and this development in our manufacturing systems will ensure that the
        commitment continues and that consumers receive Novogen products of the highest
        quality supported by clinical proof of efficacy and safety.&#8221; </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">&#8220;The
        new
        arrangements will also allow Novogen to free up cash resources and reduce
        working capital through a more efficient supply chain&#8221; he said. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">About
        Novogen </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">Novogen
        Limited (Nasdaq: NVGN) is an Australian biotechnology company which has patented
        isoflavone technology for the treatment and prevention of degenerative diseases
        and disorders. Novogen&#8217;s isoflavone products are marketed globally and the
        Company coordinates and manages its research and development programs utilising
        the expertise and clinical research capabilities of universities and hospitals
        in Australia and key international locations.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><em>Under
        U.S. law, a new drug cannot be marketed until it has been investigated in
        clinical trials and approved by the FDA as being safe and effective for the
        intended use. Statements included in this press release that are not historical
        in nature are "forward-looking statements" within the meaning of the "safe
        harbor" provisions of the Private Securities Litigation Reform Act of 1995.
        You
        should be aware that our actual results could differ materially from those
        contained in the forward-looking statements, which are based on management's
        current expectations and are subject to a number of risks and uncertainties,
        including, but not limited to, our failure to successfully commercialize
        our
        product candidates; costs and delays in the development and/or FDA approval,
        or
        the failure to obtain such approval, of our product candidates; uncertainties
        in
        clinical trial results; our inability to maintain or enter into, and the
        risks
        resulting from our dependence upon, collaboration or contractual arrangements
        necessary for the development, manufacture, commercialization, marketing,
        sales
        and distribution of any products; competitive factors; our inability to protect
        our patents or proprietary rights and obtain necessary rights to third arty
        patents and intellectual property to operate our business; our inability
        to
        operate our business without infringing the patents and proprietary rights
        of
        others; general economic conditions; the failure of any products to gain
        market
        acceptance; our inability to obtain any additional required financing;
        technological changes; government regulation; changes in industry practice;
        and
        one-time events. We do not intend to update any of these factors or to publicly
        announce the results of any revisions to these forward-looking statements.
        </em></font></div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
  </body>
</html>




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>novogen5.jpg
<TEXT>
begin 644 novogen5.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!P17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@#`P#$!`@`9````3@``````
M``!@`````0```&`````!````141'05)I>F5R(%-O9G1W87)E(%-U:71E`(#_
MVP!#``(!`0$!`0(!`0$"`@("`@0#`@("`@4$!`,$!@4&!@8%!@8&!PD(!@<)
M!P8&"`L("0H*"@H*!@@+#`L*#`D*"@K_VP!#`0("`@("`@4#`P4*!P8'"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@K_P``1"`"G`<(#`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"
M`P0%!@<("0H+_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A
M!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%
M1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9
MFJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?H
MZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+
M_\0`M1$``@$"!`0#!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1
MH;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::G
MJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W
M^/GZ_]H`#`,!``(1`Q$`/P#]_****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"N)TG7(#\<-=\*JP5H?"VEW*1XYP]SJ2D_^0Q7;5\K^(OC3;^!?^"L>A_"
M_5+E$C\<_!QTTR)I<;[NQO[B9E''S,8I9&`XP(R><\7%-[')BJT*+@Y/=I'U
M);'Y-O<`9J2JUA,T^Y]@"E5VD-G/7^F/SJS4O<Z[W"BBBD`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!7X]_\`!?\`^*7BK]FW]NCX#?M&>"9BM]X?TVZGC/.V18KF,R1G'9D=
MD)Z[6/K7["=:_';_`(.DO#@C/PB\8",X@.J6*MV^80N!_P"0Z[\M498M1:NF
M?+<82E2R:56'Q1::/U'_`&7?CGX)_:2^"/A_XV_#W4%N-*\0:7!=0@'YH6*#
M=$X[.C94CU!KT+(/0U_/E_P12_X*C2_L8_$5_@K\6=5_XMWXIOX\74B?\@6\
M9BHF&#S&V[Y^"?D4]`:_?7P_KNEZ_I$6M:)?Q75K<PK);7$+;DE1AD,I'!!'
M(]0:C'86>&JOL;\.9[A\YP*DI>_%*Z-BBCI17&?1!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`449'K10`4444`%%%%`!1110`4444`%%&0>AHH`
M***,@]#0`5^87_!SIX*DU?\`9,\&^-4CR-'\;+"YV<J)[>4`Y],Q'\Q7Z>U\
M9?\`!<_X5M\0O^"9?Q"2RM3+<Z$+#6+968D@07D+3'/M#YWYUTX.3AB8R1XG
M$5%XC):\%ORM_<?SGF3R6,!7((PQSU!SD?C7Z8?\$8?^"QU_\#-7L?V6OVH/
M$C/X-N1Y/A?Q%?SD_P!CS,V5MI6.3Y#$L`3]S`'0"OS,G1@0Q;)R<^XZ`_F#
M3S=)*@5U'`(!QR*^NQ%&&)ARR/P'*<VQ.2XR-:CTW1_7AIFNV6K6D=[8S1RQ
M2*"DB2`JP(R"#T(]".#5Q6W?_KK\5?\`@B)_P5VO/`VN:9^QY^T[XHEET6[G
M\CP7XEOI<_8VV#9:2N?^69;Y4)R59U0GFOVCL)4E3S$;(95*\Y&.>]?(XO#3
MPM7E9_0&29SA\YP:K4WKU78L4445S'LA1110`4449%`!111D>M`!1110`449
M'3-%`!1110`4444`%%&1ZT4`%%&1ZT4`%%!('4T4`%%%%`!11D>M&1ZB@`HH
MR#T-%`!1110`449`ZFC(]:`"BBB@`HHR!U-%`!1110!CCQ;X:;Y5UVR)/11,
M.:N:;JFFZ@C/97<4R@`DPG<._I]#7\L3Z[J[J4;5;O!ZXN#7Z`_\$-/V_KOX
M3_$^3]F+XG:T&T3Q=>)_PCEU=S$+9:FQ*K""<X28E5`SPX`&=_'@8?/J5>NJ
M;5KGZGGWA;CLEP,\13J^TY5>R70_:=65E#J>#TI:J6U])+"K_9^&4L.<=^E6
MQTKWS\KOJ(V`<FLW5_$FB:4WDZEJD,#XR$=\''KBK\_0#-?C7_P<<ZAJ%C^T
M=X)6QNWB\WPPY8HQ'/G,,\$9/3KGI7+C,3]4H>T/>X:R&?$F<1P*ER\UW?TW
M/V#TG7M(UR#S])U&*YB5RK/"^X*<9P<=#R./>M.,`$L.X%?G1_P;C7&H7W[+
M?C*>_P!1FGQ\0IE3SY2Y5?L%EP"Q)QG<?^!5^BJ-MXQTHPM=8BBJO<Y,ZRQY
M+FM3!.7-R.UR2H97$:;V'%.,[`X*C\Z^>?VYO^"BWP6_8B^'O_"0^-;A;_7+
MQ&_L7PW:W2"XO&4X8Y_Y9HI/+GC/`R2`=ZE2%&'/-V1R87"8G'5XT</'FD]%
M8^@%O;91F255STR<9KA_'/[3W[/GP[NFL?&WQF\-:7,K;6AO=7AC=3Z$,V17
MX2?M3?\`!5W]K?\`:GU>YAN/']YX7\.3RNB:%X;O)+>,Q$`[99E(>7`X.Y@A
MSRO-<7\(OV#?VS_VA[=?$7P\^!GB?5+2?YEU6_A,$++TW1RW!C60<8RA8<<5
MXTLZC4J.%"#D?J.'\+7A*,:V;8J-)-7M=7/WPT+]NO\`9!\42+;Z'^T?X0F=
MVP@.N0J"?Q:O1]!\5^'O$%H-0T;7;.]MY,>5/9SB1'^A4D&OY\_%7_!)3_@H
M9X/TXZWJO[-VJW"1+ND_LV^M[F1![)'(9&^B@FO./AW\;/VGOV3/&[GP1XS\
M3>$-7MI@MUITC2P[BI.%FMY!AP/FX8'&3TS6+SNO3E:K2:1HO#++,?%O+\PC
M*72+:U/Z8O.\S)@8>N&%<E^T1\-;+XQ_`;Q=\+;JW2:/Q!X=O+`Q2?=8RPL@
MS^)%?!/_``3O_P""Z6@?%W5-/^$/[4MI9:#KEQB&R\3POLLKURV%1P?]0Y&,
M98@D'[N=H_1O[:MQ8F6T*RJ0<$-U!Z&O:PF,I5Z<:E+8_,L^X?S+**D\)C86
M=FK]'\S^1SQ#HE[X:U2X\-ZG$\=UI]P]M=1.FTI(F%88/3IT[<BJ-?4W_!9;
M]G^X_9]_X*"^/-,$&RR\2ZE)XBT\K'A2EY(TCJ.V%E\Q?H!TSBOEN-%<X9\?
MA7Z)AJT:E&+1_)V94)8;'U*;5K-DUHS9WB0JP!VL.H/]?ZU^X?\`P06_X*A7
M/Q^\$_\`#)OQU\1^=XP\,V"?\(WJ=VY:76+!`5VNQ^]/$`N3U=6#=0^/PV9R
M3QQ72_!SXL^.O@?\4=!^+7PVU>2PUS0-3BN["YC;'S*P)1A_$KKE&7H58@\&
MN?'8*.*@V]SU.&\\KY+CE):P>Z/ZU;<QM$/+'&.YJQTKQ#]@W]K'PO\`MA_L
MR^&?CGX7DA"ZI:E=2MUE):TNT++-$01G(<9&>JD&O;Z^-J1=.HX/H?T1AJ]/
M$X>-6GM)7#I4<L\,0WN3QZ*33I&((`&<@]Z\+_X*%?M'/^RU^RIXO^+<-TD-
MY;Z>;?1RSX)NY@8HL<'.'=6_X":RJ35.#D]D=>&H5,5B84::O*3LCUV?QOX3
MMLF?7[50OWBTX`'XUJ6TL<R^;$<AE!!QU!K^;S]@#X.>*?VG_P!L#P;\*QJ5
M^UE/J:W>LM'=,/*LX5\V0DCH#M,?^\P'>OZ-O#\)L-/AM$B(184"!CS]T<5Q
MX+&1QD.91L?2\5\-QX9Q,*'M>>4DI/R3-(G`ZU3:YLE(,THR>AP:\,_;C_X*
M&?!?]ACP0GB+XAW`OM6O&*:-X<L9P;J]8#J!_`@/!<\9(')(!_&C]K'_`(*X
M_M>_M0W]S;R>.[GPAX>D^6+0O#-]);@(3SYLX99)3Z\JI'&RHQF98?"RY'K+
ML5P_P9FW$252FE"EUE+8_=CQW^TK\`OAI<M9>//C%X<TJ>,9>WO-7A21!_M*
M6R/RKG-!_;N_8\\3W/V30OVC_"-Q(&P476H0<_BPK\"_A/\`L,_MC?M'6R:S
M\-_@1XAUBT?F/5I[<002AN=R23LBOTY*Y[9/2NM\3_\`!)'_`(*">'].:[N_
MV<;^^B@^\FG75K=2(3SS&DA)_`5P+.,8UI1=C["7AYD%"?LZV90Y_)Z']">D
M>*?#'B.QAU/1==L[RVN!F"XM;A7CD&,Y5E.#P.U7[9PY8AP1Q@"OYF/!'QF_
M:?\`V0OB`1X5\9^*O!NMVI'VO3[F66`L.0!-;O\`+(/<@CWS7Z<?\$Y_^"[6
MB_$K5+3X0?M96EEHFM7+Q0Z?XGB<QVEW(3M`F5LB%B=H#`["6QA>,].%SBA7
MER5%RR\SR,]\-\TRG#_6<+.->EU<=S]-:*K6.I1W\"W,&UT<91D?(;Z&K->P
M?G*=PH/2FRR&-=P7/':O(_VK?VT_@M^QU\/I_'WQDUU+1`=MC81.&N+V0CA(
MDZL>Y/11R3BIG.-.#G)V2-L/1K8JNJ-&+E)[)'J)O[2*,RRW2A=P'([GM7/>
M,_C5\)/A^BOXZ^)&B:0-F\#4M1CA.WUPY%?B)^UI_P`%LOVJ_P!H?49M$^%N
MMMX!\/898;?1ILWLBJ?O2W"\J2.=J;0,9SC->">"/V:_VO?VEKEM7\&?##QS
MXQ:X</)JK6MS<PR,Q)W//)\N3@\E@#CJ<5X<\ZO*V'AS(_3<O\,JSP_M<UQ4
M*'EU/Z"!^V_^R(SB)?VCO!Q+=`-<@Y_\>KJ_#?QX^"OC"X2S\*_%3PYJ4TA(
M2*QU>&5C@9/"L3T!K\"5_P""2G_!1<+]I'[+NJ$@<$ZGIY8?@9\UQ'C;]D']
MLCX+1MJ'C/X&^-M$MHL-)?V^DW7D]0`3+""@YP`<]3VZTEG&)7QTF=R\-\AK
MZ8?,X.79L_I174+25]B,C8&>/>K","N0N`.U?@+_`,$__P!O[]N?P3\;O"WP
MB^'_`(\OO$]KK>MV^F_\(]XDGENHXU:55;:[,9(BBLS,0Q`"\C@5^^6DO<2:
M7"]V`)3'^\"]-W?&:]3"8N&*H\]K-;GP/$W#&)X:Q4:56HIJ6JL^A:+*$!)^
ME9USXBT"TN7MKO5[:.0`$QRR@'!Z'!_G5R0%T4`]".W7FOQ)_P"#@/5=4L?V
MS-,M(-1G6-?"%NP6.8J-WFR@G'3)P/RIXO%+"4'5>I'#&0?ZQYI'!<_)=7N?
MM./%?AGOKEE_W_6D_P"$K\,_]!NR_P"_ZU_-G\+/V:?VL_C=X=;QA\(O@]XQ
M\1:5'</`^H:5932Q>:H4L@9006&\<5T__#`?_!0+_HV?XA?^"BX_^)KRXYS5
MDM*3/NZOAIE="JZ<\S@FM&K_`/!/Z)O^$J\-$9_MNRP.O[]:=!XK\.7;^3!K
M$#L.BI(">W8?6OYUF_8#_P""@GWA^S-\1"!UQI%QC_T&O>O^"97['G[9/P\_
M;6\&^-/B-\"/&.EZ'933&^U#5M)F6"%3#(`&8C'WMO7-:4<TQ%2I:5)I'FYE
MP+EF7X">(IYA";CT35_S/W$R#5>_U*PTU!-?7*1+@D,YP..M3K]T9]*^0/\`
M@N4UU!_P3Y\4WMI)L>*YL_G`Y`-Q&"`1R,C(KUJLU3I.?8^"P&$>.QE/#IV<
MFE]Y]4?\)AX8G?9'KEH2#C!F`_K5U+N$LH2,$,,A@*_EB_M[65/_`"&+PD<9
M%R1_*OVH_P""(W[?,O[1?PE'P2^)&L+/XO\`"=N%6:>8M)?V(&V.;)Y9@0RM
MUZHW\6!Y66YQ3QU5P:MV\S[SBOPWQ_#F7K%PJ\ZZKL??T9&XCOBG5#;.9)'.
MWY>-K`]:FKV3\XM8K7#0Q@%SP.Y%9C>-?"B7<EJWB"V$L;E)(_,&4(SD$=NA
M_*M&]ADE@<1S;&*D*VW.#ZU_-[_P4`US6X?VV/BO!)K5Z\<?CS50(S>.$"":
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MF+]L;]GR'3/%.LC_`(37PK$EGXAB9UW7*\B*[7CE77&>.'1ATKZ]R!P37\U/
M[&'[4?CW]AS]I&P^*.GVER#9SO9>)]%W8-Q;9(FB*G!5E*@C/0Q\]17]%_PQ
M^)W@OXO^!M*^(G@+5XK_`$K5K1+BSN8B</&PR#SR/0@\@@@\BOHLGQGMZ/LJ
MC]];GXGQ[PS#(LS=?#?[O5O*#[=U^)TD^"`:_&;_`(.0`#^TCX&SV\*N?_([
M5^RSLI..^17XT_\`!R!_R<EX'_[%1O\`TH:GG;_X3I'1X6K_`(S*C_AE^1]!
M_P#!M[Q^RGXR/_519O\`T@LZ_10D;]N>HK\Z?^#;X_\`&*WC+_LH<W_I#9U^
MBY568ENP%:91_N<3Q..K?ZUXJ_\`,_R/,OVJ?VC?"?[*/P5USXT^-ILVFDVQ
M:*V#A6N9CQ'"F?XG;`%?SK?'[XY_$K]JKXM:A\6/B+>2ZAK.K7(BM+=%+_9T
MW8CMXE/.Q"<`#DD^M?HC_P`''GQ[N+K7?!7[-NE7[+;P!M:U:->DCMNA@!^G
M[T_C7A__``0V_95L_P!H']J0?$;Q3IHNM#\!P+>2PS1Y6:^<LL(;_=(:;']\
M`]J\;-:\L=C5A(GZ3P'@L#PUPM5SW$1_>-/EOWZ?>?5__!+C_@C3X+\`>%M-
M^/'[4OABVU;Q1>QQW6E>'KZ/?;Z4A&Y#*A!$LX!SD\+G`&<U^C5AHNEZ3IZ6
M.G6,<$,8Q'%$H"J.P`'0"K5G%Y>?H/ZU/7TF&PU/"TE"*V/R'-\YS#/,7*OB
MJC=^E]$5?L=M(C12*'5AAE89!KP[]M']@;]G_P#;)\"OX?\`B+X+M4U6&-O[
M'\0V<"I>6,N`%9)!@D#C*'*D#ITKWNHKDD8(]#6E2C2K0<9JZ9P83$5\!5C4
MH2LT[H_FD_:Z_93^(G['OQGU'X4?$"RWO$OF:5J,$96+4;7(VS*3W7."ISM8
M$=1FOT\_X(8_\%"M4^-OA"?]F'XOZY)>>(_#UK]HT/4+B7,E_8C"&-L\M)&<
M$GNLBYY!SZ-_P6\_90L?V@/V4;[Q[I&CH_B'P0&U*QN`GS/;`#SX21R5*@-]
M8Q7X[_L=?'#4?V=OVF_!?QAT^[=/[(UJ$705MHEM7)BEC8#@YC=QGWKY50>4
M9@HI^Y(_?/;4?$#@R<JZ3Q%'JM]%I]Y^C/\`P<N_LIMXZ^"GA?\`:=\*Z-YN
MH>#;J33];:,'+V-R4\MFYY,<JA5]YSGH*_$ZXMM@RIQ[BOZO?B?\/_!O[1/P
M>U;X;^*[-;S1?%.C2VMW$QX:*6,C<O<,-P*GL0I[5_,1^UG^S;XT_9+_`&@_
M$O[/OCM#]JT"^*V]TR[5O+9@'AG7/9XV4^QW`X*D#]1RG$J4?9G\.>(635<-
MC5C8K=^]IM;3]#S.GQJQ0NAP58$$=B#D?RIE/B(`;-?0-I:GYC=K8_2O_@W)
M_;%G^$_QVU#]E?QEJ[#1?',+7.A!Y.+?4X@H*Y;H)8L@8_B11C+5^ZV1ZBOY
M'_A/\2?$7P;^)>@_%7PG<B'5/#NJ6]]9,6/^LBE$@''\)`9&'<-7]5'P1^)>
MA_&KX6^'?BSX78-IWB+1X-0L3NY\N6)9`#[@LP_"OE<WH*-7VBZG[7P!FCKX
M&6'F[RCJO\CLYY-K`>H.*_)7_@XT_:,GO-<\*?LPZ/J),,.-;UBWC8?,Q62.
M%6[\`R-CU(/4`C]6?$6HV6BZ0^JZF^R&VB>220C[@522WM@`U_-_^V/\8M7_
M`&N/VO?%?Q%TN.:ZEUSQ"+31+>-<EK='6"VC0>K(J'\SV-?%9[B)0PGLX;R/
MZ-\+\I6/SUXNJOW=&/,[[7/T`_X-SOV:([;P[XJ_:GUK3MHN[HZ)X?:099HD
MVR7#@^F]E3ZQFOT*_:C^/_@W]F'X'^(?C9XWO#%9:)I\DZQJ?GGDP=D2`]79
ML*!ZD5E?L<_`2V_9B_9T\*?!BQ@7&DZ:D=[)&`!+<L`TLGXN6-?G[_P<<_M`
MWT$/@?\`9KT*Y:..83ZUK<8;J1B.U!_V0WG,1URJUHY/+,J4E\21P\D^->.)
M4U\,I_=%:_H?G9^TM^T/\1_VJ/B_JOQ:^)NIF[O=2FVP6@;=#:0#`2"-<8"J
M!CIR2Q.2Q)_3O_@EK_P1I\)>!]+T[XZ_M8^%8=4\0W'[_2O#%ZI>WTU"ORM-
M&1B2;D\-E4(!QN'R_*?_``1"_92TW]H7]K3_`(3;Q1IJ3:#X%MUU*9)4W":]
M:0"V7GC@JSG'=/<5^\R(%4+C@5PY1@8XC_:JVLGL?9^)'$U3+9+(\LER4XI<
MS6FI0T[1=)TFT2RT_3X;:%%`CAAC"JH`P``.@]JG^S6I<.5!(Z$CI5FBOI.5
M7/Q'WGJW=G@W[8G["G[/?[87@.X\.?$WP5`=0\EAI>OVZ[;NS<\@H_IVVG*X
M)XK\&OVQ?V1_B-^QK\8KKX6^/87DA7<^AZLL;)'J%J#A9ESRK<_,O5#QG(S7
M]+K`E?EZ]J^-/^"V/[)%E^T?^R5J/C#3],637?`5M<ZSIT@`WO"J`W,0]=T2
M%@.[Q)UQ7E9IE]'$4_:)6DNQ^@\"<7X[(\>L-4GS4*CLT];7/'?^"%7_``4*
MUSXN^')OV4OBSX@:ZUOP[8^=X;O+E_WEY8J?FBSU=XLK[[&7.2*_2ZOYBOV5
MOC;J?[.?[0/A7XT:5=R1_P!C:Q#<7JQC)D@9]L\8_P!Z-B![*1W%?TS:=JUK
MJ=C#>VTRR+/$'C93D,",Y%3D^,GB*3IR=W$OQ(R&EDV;^VH1M2JJZ]>OYG*?
MM%?&7PQ^S_\`"C6/B]XTU-;72]"T^6ZNF+`%]@R$7/5F.%`[E@*_G9_:_P#V
ML_B9^V=\9[WXL?$"_F,<K^5HFEJ2(K*U!'EHBCN>&+'))8\XK]$_^#C?]HRZ
MTWPGX+_9OT"[=1J\\VK:['&Y4F&(I'`GIAI&E8CK^Y'J,_-/_!#+]DBS_:%_
M:G_X6%XLTM)=#\`01Z@T<JEQ/J#2+Y"\\;5VM(>^8X_>N',\15Q6+6%CMU/K
M.",!A.'.&ZG$.)2<]>2_X?>SZC_X)??\$8/!_A71M-^-O[7OA*'5M=N5$^F>
M%-07?!IH*Y5ID/#S<G@_*N!P6!V_I9HOAK0?#UBFF:'I,%G;QJ!'!;1A%08Z
M`#@#V%:84*,`=*6O>PV$HX6GRTT?DV<YWF6>XR6(Q<VV^G1%86D(X$>WUP<5
M#<Z+I=]9FUO+*.2,C:5<=JOT5NDK:GDJ\97B[,\BM?V+/V8=-^-MC^T+I/P?
MTFR\7V$$T,&KV<9B=Q(NTEU0A78#(#,"1N;!&37J<6(8C'M(VKG![5:P/2BB
M,(QO9;FE>M6Q$E*I)MI65W<KD_)GW7^8K\0?^#@\Y_;4TW_L3[;_`-&RU^WK
M_P"L;ZK_`#K\0?\`@X.Y_;4TT?\`4G6W_HV:O(SM7P27H?H7A9*,.+8.7\K/
ML;_@WE@CD_8?U$L@&/'M\=WOY%M_@*^^?*@_NC\J^!_^#>9T3]AK427`_P"*
M]OB1G_IWMZ^^MT`&1M_*N_`7EA(W['RO%C3XFQ7+I[[_`#&BWB8@@X`ZC'6F
M-:V[,=L*G=][MG_.*E6XB0X+*`>].9]V'09!Z&NKJ?/KW%?N2#I7R%_P7+D"
M_P#!.KQA'GEKBR_]*8Z^O:^/_P#@N?\`\H[/%W_7Q9?^E,=<^+_W:?H>]PY%
M3S[#1?\`/'\S\:OV&_V=+?\`:H_:#@^!]Q-Y<NL:+JAL9W)"PW,5C-+"_P`I
M!.)%3(.1ANE9_P`&OBC\7/V)OVD[3QCIMI/I/B#PIJK0:GI]PV`Z_=FMI`.-
MK(2.F1P1@@$>T_\`!#[!_P""DG@T#_GQU/\`](I:^E?^"]G[!,TT0_;-^'NB
M;!"D5MXTM[8`;UW;(KX@=QOV.?[NTX`0FOD<-AJE3`QK4='%L_H',\_I4>+9
MY1CG>A6BK7Z/5'Z1?LN_'_P9^TQ\'='^,?@6_$NGZQ813+&S#S+=R/GAD'\+
MHV58=B*]%!!&0:_#;_@B-^WJ/V>_B_\`\,\^/]4">$O&MU''8FY;"Z?J!)"@
M?W5DW%6ST(7.,&OVZL9;<VH:$;E;)#8ZGO7U.`Q4<70YENC\)XLR&IP[FLJ#
M^!N\7W3+$_$1^AK^:_\`X*$\?MO_`!='_4^:O_Z.>OZ4)_\`4GZ5_-A_P4)_
MY/@^+G_8^ZO_`.CGKS,^_AP]5^9]MX0ZYMB%_P!.S]-OV9/^3;?A[_V(^D_^
MD<5%2?LQ?\FU_#S_`+$;2?\`TCBHKK6QY567[V7JS\>O!0_XK/2!_P!12W_]
M&+7]07A>W^T^#;!&;@V,088Z@H,C\J_E^\#_`/(ZZ/\`]A6W_P#1JU_4+X*.
M?"M@A_Y\XL?]\"O.X<;E2FV?2^,S_?X677E9^.__``7:_8*7X1_$`?M5?#C3
M2-"\2W*KXF@MHPJ65^1M\\@=$E4-N_V\G^+C6_X(/_\`!0!_`WB\?L@?$[55
M_L[5YWG\)W%U/_J+DJ2]JA(QL;864<89B.=W'ZJ_&WX*>`OCU\.]6^%GQ&TI
M;W3=7LGMKB%C_"V""/<$`@]OQ-?SM?M2?L\_$O\`8<_:1U#X<ZS<7$&H:#?)
M>:'K$49C%S#NW074?<#Y<''\:N.F*>84IY=CEBX+W>I'">-P_&/#TLBQ;_?1
M5X-]?^&T/Z4+>=;D>8%&.""#U'-?C?\`\'('_)R7@8YZ^%'_`/2AJ^^?^"6/
M[;6G?MH?L\P:WJM_"/%.@+%8^*;-6`9)PI"2[>H215WCW+>E?`O_``<A'/[2
M'@7:?^97;_T>U=>;5*=?*G.&J9XWAU@L3EW'D<-65I04T_N/H/\`X-OE_P",
M5?&9_P"JB3#_`,D;.OT5D&3G/45^=?\`P;?_`/)JOC/_`+*+-_Z06=?HJW/Z
M?SK;*E_L,3YGCG7BG%_XOT/P/_X+J>)+K6_^"BOBO3)KG>NDZ;I5G&@;.P&R
M6<`^G,\A_$5]M_\`!N5X,M-._9/\4^+XPBW6J>/+B">0)R\,-K;&,$YZ@RR'
M_@5?%_\`P7C\*W/A_P#X*&ZWK.`!K>A:==H0@Y"VYMN?7F(5]@?\&W/Q#L]5
M_9\\:_#1[M/M6D>,#?>6#UAN;:)5/YP/^=>5A(0_MR4GN?I/$,:L_"O#>S>B
M<;GZ2VRE4&6[8Z5+3(?Z"GU]2?AK=V%,FC\SOC@T^HYG*E0.]%KBD[*YC^,?
M"FF>*_#&H^'=802VE]8RV]S$PR'C=&1@?JK$?C7\N.JZ<NF:K/IK2^8L%R\3
M-C&X*Y4GVX%?U"?$_P`;:9\//`>M^-M;G"6>D:9/>7+9'"11%R/TK^7>ZFN]
M7U9[J67#W,I;9@<LS$G]2:^8XE2_=/JG_D?MG@^I^SQDG\-E]_O']*_[%>MW
M?C']DKX;>+=3E$EQJO@'2+J=RO)D>RB=B?7):ODC_@NO_P`$UY_VL?A3%\=?
MA+HAN/'WA"V;%K;Q_/JMB`6>`=S(IPR=>K#C.:^QOV2_"DO@7]FCP!X)G4*V
MC^#-,LBH[>5:QQ_^RUW\EK#.I2;O^E?586K.DHS3ULC\-XAP%#-'B*$]G)_F
M?R%FQDC9XIB5DC8K)&1RC`X(/I4()0D$5^KO_!;G_@C[=^&+_4/VROV8?#$S
M:9(GF>-O#.GP;FM\')O85'.W!'F)CY=I88`(K\IK@JP5U7&[)QR>.,<D?_JK
M[3"XE8J-T?S=G.38K)L6Z51:=!/.!P#&/SK^@?\`X-WOC?+\5?\`@GS8^$[^
M^\^_\#>([S1959OF6#"7$!QV&R?8/^N9^@_GT'45^K/_``;`_%N;2OBI\3O@
MQ/>A%U32+35;:`GEG@D>-L#UVS+D]^/05R9O24L-=;H]W@+%?5<\2Z23/OG_
M`(+*_M%K^S[^Q)XC73K_`,C5_%D1T#2V1L.IN5*2LN.XBWX/8D5^7/\`P1,_
M9X'QS_;4TC6-8T83:+X&M3K=Y(02AF4K';H?]K>V[_=1J])_X."_VBY?B%^T
M7HGP)TS5!)9>"[*2:]1)1M-Y<E2RMC^Y"JX/4;LC!YKZU_X(*?LZ?\*G_9*_
MX6QK>G^3JGCR[-T"W#)9PLT4(/\`OX>0?[+BOS*<5CLTBEM`_M^A_P`8KX<R
MJ;5<4[>?+V^X^\)8R5(#``K\HQT-?@W_`,%U==N=8_;_`-7MKB=F%CH5C!&A
M/"C:S\?BQK]YI&`5]WW0.N.E?A/_`,%Z_"]WH?[>=WK,BC[/J_ARRN+9MN,A
M0T;?7E?UK?/_`/<3QO"F4%Q4HRW<;'UW_P`&YO@2RL_V;?%OCI#B?4_%I@D)
M&?DAACVC_P`B/7Z2D'&`<5^8_P#P;C?$JUO/@KXW^%TETAN-.\11WL4.>?+G
MA"Y_.%C^%?IQD=,UU94_]@@?/<;PJ4^*\5">ZD%%%%>@?*A6%\1]*M=<\':E
MH]ZH:*ZL)H9`1D%60J>._!-;M<S\7O%&F^"_AYK/BO5[A(K73=(NKNX>1L!8
MXXB[$^P`J*G\-FM!2=>'+O=?F?S!^--&M/#GC+5_#UB28;'5;FWC+=2$E90?
MTK^D']BC7KOQ?^R9\.O$=Y<%WN?!VG.[GJQ^S1J23[E2WX^U?S>>+=9C\1^*
M]3\0HH47^H37(4'IYCL_'YU_2=^R9X3N_`/[,?@'P;?0>5/IWA'3X)XQGB18
M%##\Z^:R&*6+J-'[9XM17]CX!3^)I?\`I*O^A^.O_!>[7KW4OV^+O1IY-T.F
M>&;&*W![!O,<_JU?87_!N7X5T^Q_9@\6>++?B[U+Q<8)FV_P0PQ[1_Y$:OD_
M_@X%\'W6B_MQP>+&C80:]X1LIH21P?++QM^H'YU])_\`!M[\3;/4OA/XZ^$L
MMTGVC2]:BU&*(?>V31A2?SB`J,-_R/))FF>P=7PIP]6EM[M_Z]3].Z***^K/
MPH*8TI`!"]:?6;XCOY=-T&YOH)-KPPED8C(!QZ>E*^HXQ<I**W;L:._CGTIO
MFC&<5^&]Y_P7D_;[MO&KZ5_:?A3RDU1K<J/#9;:GFE.<2Y!Q@Y/KTK]L?!&M
M3^(O!^FZU>,#-=6,<LQ48&\J"<#L,YKFPN+IXIRY>A[N=\.9IP_&G+&0LJBN
MC1?[S'W7^=?B%_P<'C'[:FFG_J3K;_T;+7[>OU?ZK_.OQ"_X.$/^3U-,_P"Q
M.MO_`$;+7GYW=X'3^MCZ7PO:7%M/TZ'`?L3?\%:OB]^P]\)9OA)X#^&OA[5K
M2;69M1:ZU2:X$@>1(T*XC<#`$?Z^W/L7_$1O^TW_`-$4\&_]_P"\_P#CM=A_
MP1R_X)U?LC_M7?LM7GQ$^-_PT.K:S#XLNK-;H:K=0_N4B@95VQ2*O!=CG&>>
MM?7'_#D7_@G-_P!$+;_P?W__`,>KEP^'S=T(^SJ)+S1]=GN=>']#.*\,5@Y2
MJ*3N[O\`S/A4_P#!QI^TRQWM\$O!IV*2/W]YP?\`O[7ZG_L;_&[7/VAOV9?!
MWQL\2:7;65[XBT6*]NK2T9C'"SY.%+$DCZUXQ+_P1&_X)S@9'P/9?7_B?W_(
M]/\`75](_"KX7>#O@KX"TKX6_#S118:!H=DMMIUGYSR>5$O1=SDLV/4DFO4P
M5',(/_:)J2\C\^XHS3A;&481RO#NF[Z[_JV=9UKX^_X+G_\`*.SQ</\`IXLO
M_2F.OL$8QQ7Q]_P7/_Y1V^+O^OBR_P#2F.NG%?[M/T9Y?#/_`"4&%_QQ_,_,
M/_@A\<?\%)O!I_Z<=3_](I:_=SXA>$/#WCKPAJ7@_P`3Z5%>6&IV3VMW;2Q[
MEE1QM*D'C!!Q7X1_\$/S_P`;)?!O'_+CJ?\`Z12U^^KQQ[?GR?>O*X?2E@&G
MW9]EXK2G#BE2@[-1C^;/YR?^"@G[(OB3]BG]HJ]\!"*Y.@W<C7_A34V./.MM
MQ'WO^>L>5!P<@D-WQ7ZN_P#!''_@H(W[4_P+C^'?C>]CD\;^$+9(-2)?#7MO
MNVQW2J>3P55CS\V#GY@*[[_@J?\`L0Z3^V;^SG>:+H]G"/%6@1S:AX5N)(P2
M;E5!\@GJ$EVA#[[3VK\0/V9?VB/B3^Q%^T99?$W1(+JWOM%O7L];TE_D:>`-
MB:W;CDDJ`!TW(#U`KAGSY/B[Q^"70^DH>R\1.%72;_VJ@M/-?\,?TM2MFW+>
MU?S8_P#!0H#_`(;A^+H'3_A/M7Q_W^>OZ&_@I\9O"'QZ^&>E?$_P)J\=YI>K
M6B3VLJ,#\K#H<=&!R"/:OYY/^"A*[?VX_B\GIX^U@#_O\]=6>ZX>G+S7YGE^
M$U*I0SO%TZFDHTV?IQ^S&^/V;/AZ,?\`,CZ3_P"D<5%-_9D_Y-M^'O\`V(^D
M_P#I'%17<HJQY%5+VLO5GX_>"_\`D<=(_P"PK;_^C5K^HGP)_P`BII_'_+G%
M_P"@"OY=_!`#>,](4G'_`!-+?_T8M?U$>`]P\*V".,,+*+(_X`*\SAQKV<T?
M2>,;7M\(KZJ+-BOA_P#X++_L#7/[5/P0E^(W@/2U;QGX0M6FTX``&]MLAI;8
MXYY&YE_VA[U]P54O;6+[*[7$F4"?/NZ8KW\10AB:+ISV9^1Y9F>*RC'T\5AW
M:47^'4_G-_X)Y?M@^(OV)/VC]-^(-PUU_8EW*EAXPTT-S-;,Q5F"GK+$VYN>
M?W;`<G%?1/\`P<#>*_#/CCXQ_#GQIX2U6*]T[4O!1NK.Y@Y22)I&*M^(_6LS
M_@MG^P._[.'QA'Q\^'^F`^%/&MU+)=)''B+3M3#>8X(_A23<SKZE67C.:^._
M'/Q7\4^//!GA3P/K\I>#P=:7%II+L^YEMY9_/6(^H1BX'L0.W/Q>)K5L)2J8
M.2]/,_I+*</@^(,VPG$."TDERU%W6S;^9^M__!M]S^RMXR'_`%4.;_TALZ_1
M<G#X'<5^=/\`P;?+G]E3QF<]/B'/_P"D%G7Z+JIDRP.*^HRI..#C<_!^.+3X
MJQ37\Y^7W_!QG^SS?:YX6\)_M)Z!9/(=$D;2=;*1[MEO,1)%(>^!)'L^LJ5\
M<?\`!(3]KS3?V3OVM;"X\87GV7P[XJC.F:S(6.V-W.Z"7GIME)5C_=D)[5^[
MOQA^"_@[XW^`M9^''CZR2[TK6[![2\MW0?<88W`]F4_,#V(![5_.[^V[^Q7\
M1_V)?C%=_#KQE8RW&ESS/-X=UEHCY&HVW(['@CD.F<\\''(\O-J53"8J.,I*
M]MS]'\/,?A.(,CJ<.8N:BW?E;ZW_`,M#^D/0K^SU*V%W83+)"Z*T;IC#*<D$
M8]1S^-7J_''_`();?\%KX_@KX=L?V?\`]J-Y[K0K6-(-"\5KOEDLHE)`CN1\
MS,B@J!(/NA<$=#7ZN_#KXZ_#'XL>&[?Q9\.O&VDZS87*[H[K3KY94(R1U7Z=
M#R*]G"8ZCBZ2DI*Y^89_PSF?#V-G0K0;BG92MHUT9V-07LD*C9*"=RG:`.OM
M56]\1V>FVWVS4)8HH@I:1WD`"@=R:^._V[_^"RG[._[,FB7/ASX?:U8^,/&C
M1R1VVDV%T&@M9,?*UQ,,H@!'*@ECC&!G-;U<11HQYIR2L>;@,KQ^:5U1PU-R
MD^R.`_X+S_M@:+\)O@$/V?/"FKHOBCQF5AO(T8%K32URTC^Q=PB#ZD_PU^97
M_!/+]GK4OVFOVP/!?PRM[-Y+,:HE_K+A,K':6^)I-W8!L*GUD'K7"?%KXL_%
MC]ISXM7GQ$\?7MWK?B;Q%>(#%%$S._\`#$D4?)`12451R!@X;J?V@_X(Z_\`
M!.S4OV/_`(;S>/OBC91)XW\2QYO+<*"-,ML*4M5()&X-N9R..5'\()^7C[7.
M,SYK>Y$_<\4\'X<\&RPBDI8FK&[?6[W7R/M70K(V$36Z*!$BJL:J>@`Q^%7R
M,C%16\?EDC=V'%2U]=9+1'\^)R:O+=Z_>4M2M(=1L)+&XA62.9-LD<B@@@]0
M0>V*_%C_`(+/?\$6[[X57&I?M:?LJ^'"^@SO+=^+_#%JNY],8G<]W;+SF(Y8
MM&,[>"HP3C]L3$>S8_"JNIZ9;ZE$;2]1)(G0JZ.F0P/4$'MCC\:Z,+BJF$G=
M;'BYSDF$SG#\E5>\MF?R(2)%<J&0`#`/#<8_PK[`_P""'_QNT;X'?MZV'B77
MKQ8["]\&ZW'<R,,!1#9RWI'/3(M%_/'6O:O^"YO_``25L?V>?$%S^UA^SKHF
MSP?J=V#XJT6TC"C1+B0?\?$>,%8)&!##D(\@Z*>/SC\(:A>:=K=G=6EQ)`Q9
MX6DC?:2DB%&!/8%6(/L37T&(Q'M<MG..ME=GY+DN2U,MXSPN$KNT95(QOY-G
MTE96_C3]N_\`;.5Y3++JGQ'\<;CA>(89YMQ8CLD<9P?]F,BOZ-/A1X)T/X:_
M#G1O`&@6?V:QT;38K2TA'\,<:[%_,`'\:_(C_@WA_9I;QU\;?$O[1FK6F;/P
MA9QV6EN\>0UY<AG?'^Y&.1V\X<\5^R=O:J8E\N8D;<`XZBOSS(Z-J,JLOM-_
MF?V#XFYFJF94\MI.\*$$OG9?H3SH9K9HU&2PQ_\`7K\R?^#BW]G#4O$OPW\(
M_M(:!IK22>&9)=.UUD3</LLS*T3MZ!)L\]O-R>`:_3I5V@#/2N6^,GPN\+?&
M+X<ZO\-?&NFK>:7K.G36E[`ZY#1NN#^/<'L17I8RA'$X>5-]3XOAW-)Y)F]'
M&+[+U^>C_,_!#_@E!^UQ:_L@?M:Z=KOBO5?L_AKQ+!_8WB#<^$CC=PT<[9Z;
M)$3GLK2Y^\*_H,M-3L]0B2YLYDEC<`JZ'((_K7\X/[='[%WQ'_8<^,EU\/\`
MQ7833:%<R[_#>MF/]UJ$)`PI8YQ(HX9.ORDC.:^L/^"7/_!9]?@;IEA\"?VH
MY)[KP[:*(=+\4;C)/I\0&U8YDY:2,'`5UR5!Y!QFOG\MQLL)-X>KI;8_6^.^
M'(<2TEG>5>_=+F2W?_#'[,QGDBG5QOPV^.OPN^+N@P>*?AEXRT_6M/N(U9+J
MQNA(N",C.W.T^S8/'2NBN?$-G:PFXDFBVCJ1)G'UQTKZ=3@U=-?>?B%2C6I3
MY)P:?:S+4LJPC)%?`W_!=G]M;1/@_P#L\CX`>$];4^)/'D3V]PEL06M=.!7S
MG?\`NK)D1XZL"^,[3CK_`-NS_@L5^SK^R[X>O?#'A+6;+Q?XR:(I#HFCWH>.
M!B<!IYAE(QU.,[N.G-?B=\7?BS\5?VH/B]>?$3QM>W6LZ]K]\%@A@0M]XD1P
MPH.0H)VA1G)Y[UXF:9BJ,73IN[9^G\`\%8C'8N&8X^/)0AKKI>WJ=1^PC^SK
M>_M0?M5>%?A186,DUK/J"76L*R[MEA`ZO-G_`&2G[LGU<#N*_I2AM62%(F`^
M50/7I7PU_P`$:?\`@G7=?LI?"QOBO\2;/R?'7BF!?MUNZ9;3K,-N2U![%B%=
MQW;`(^0&ONL#!SFNC*<-[##\SWEN>7XB<1QS_.N6D[TZ7NQ_4_.S_@X0_9<U
M'XF?L^Z-\??#&E-+>^`);C^TC'G<=.G5!(YQU\MXXW!/0;O4U^;7_!-G]L:X
M_8Q_:AT[XC3S7']AZI&=-\36R*6S9O(A+JO]Y&4.,<X5@/OU_1!XW\':5XZ\
M.77A/7K:*XL+^UEM[VWFB#I-$ZE71@>"""017X%?\%.O^"</C7]B#XHW&JZ)
M87%]\/\`5+G.@:P1G[,S#=]DF;)VLOS89L!E7/7(''FN'JT:RQ-%7?4^EX`S
MG!9EE57A_'OW9?#?[S]]_"_C#PYXTT>U\0>&-7@OK.\@2:UN;:0.DD;#*L".
M"".<UJ1D;BO<=:_!7_@F]_P5P^(?[%\\'P\^(&FR>)?`A<F.S\XBYTHD'FW+
M':8^F8SCN0PY!_7W]GO_`(*&?LG?M+Z+!J_PO^+^DS7$RJ9M+O+@6UW"Q'W&
MBEVL3U&5!4XX)KT,%F%'%T[WU/B>(N#<VX?Q#4H.5-[26J_#8]PK)\5#=X>O
MO^O-_P"568->L+N`3VLRNI&>#C^E<[\1O'?AKPUX4O;W6]8M+6+[*P\VXNXT
M7D8SDL*[95*:IR=^A\Q0I598F$5%WNNA_,IJ"E?B)/[ZZ?\`T<*_IZ^&O_(@
MZ*/^H3!_Z`*_F%NW2?X@S.C9']L@E@01DR+D#Z'C/>OZ>/AHV?`.B$=]*@_]
M`%>!D/O5:K7<_7_%Z,HX?+[_`,G^1LOT;_>'\Z_$+_@X0_Y/4TS_`+$ZV_\`
M1LM?M[)PC-[K_.OQ"_X.$/\`D]33/^Q-MO\`T;+77G&F#1\WX7R4>+(-_P`K
M_(^R/^#>'_DQ_4".WCV^_P#2>WK[^K\\/^#?7Q9H&B?L4ZA9:KK%I;2MXYO7
M1+FX5"R^1;\C/;@_B#7WD/B5X([^*M-_\&$7_P`575@:E-82*;1X'%=*L^),
M4^5_$^C[F[16"WQ*\$=$\4:<3Z?VA%_\52)\1_"UQ<BTL]?TZ61L;8TOXRS'
M(X`!))YX%=:J4V[)K[SY_P!E5_E?W,WZ^/O^"Y_/_!.WQ=_U\67_`*4QU]@]
M:^0/^"YR_P#&NKQ?)_=N++C_`+>8ZRQ37U:?HSV.&G;B#"O^_'\S\PO^"'YS
M_P`%(_!G_7CJG_I%+7[]CD#-?@'_`,$/,O\`\%(O!N!TLM4'_DC,?Z5^_HZ5
MY>0*V!MYL^R\5VGQ/I_(OU*VH1228"*"`K9XZ>GZU^//_!>C]@J7P-XK'[8O
MPQT9ETO6)H[;Q;:P)\L-T5_=W(4<*'V[6/3<<GK7[&2QM)]U\<$5S7Q0^$GA
M'XP>`M4^&_CS3H[[2=8LWMM0MIDR)$92I^A`.0>Q`-=^/P<,;A94WN?(\,Y_
MB>'<WABZ>L5I*/='X_\`_!"W]O>U^#GQ%;]EKXE:OC0?$MRS^'KB5LQV=^5)
M:+)Y42X``/&Y5[L:^4/^"@LB3?MO?%N5&&'\>:N0N><>?)@X]#1^V+^S/X]_
M8G_:1U'X7ZM-<1OIUV+WP[JN=IN;3S0T,Z'^\&7!]&5A_#7GWQ3\?:G\4_'^
MM?$?6X$CO=;O)[R\6,Y!E<$L>>>3S^-?&5<555*&#J+6#1_2&3Y/A:F:U,[P
M37LZ]-W2[GZ\?LR?\FV_#W_L1])_](XJ*/V9"/\`AFWX>\_\R/I/_I'%17UT
M?A1^,U4_:R]6?G/X-_X)V_MNVOC'2KF[_9A\9QQ1:E`\KR:0RJJB126)]`.:
M_H?\"V]S:>'+2UO3^^BM8DE&,;6"@$?45KB-!SM%.'TJL#EU'`7Y-V>#Q1Q=
MF'%4Z<\5&*<>R"D=$=#&Z@J1@@TM%>@?*'FW[4W[/?@;]I;X,ZW\(/'6G^=9
M:OITT(<<O;RE?DE3/1E;!'OQT)%?S[_&#]@O]JOX1_$S6_AQ=?`SQ9JITB^:
M!-4TCP[=3VUVG598Y$C*L&4@\'@DCJ*_I1J.2VBD.6B0_45YV.RVEC6FW9H^
MTX2XVS'A1U(TES0GO%NWZ,_/_P#X-\/A[\0OAQ^S+XLTCXA>"-9T.ZG\>S2I
M:ZSIDMK(\9L;4!PLB@[21C\*_0&'[O2A((H^(T`'H!3ZZ\/15"DH)['SN<9C
M+-LRJ8MQY>=WMO8*\S_:4_9>^#?[4?P[N/AS\7_"<&I6DP!@D(*S6\@P5DCD
M7YD88ZCJ,@Y!(KTRBM)14U:6J.&C7K8:JJM*3C);-'XB_M5?\$"?V@_A;J=U
MK_[.=['XVT4R/+%9F407]NN?]7M8A)C@D;@RGCE>17RCJ?PS_:Y_9UU42S^!
M?B!X.NH),I<+97MJQVC&%E10#TZY/U-?TSE0W!%1M:PL<F%3_P`!%>-6R+#5
M'>FW'T/TO`>*.;T:"HXVE&O%=U9_?9G\S>H?$[]L3XM.?#VO>.?B1XD:7$;6
MT^IWMT7]%VL6+<]N:]-^`G_!)/\`;G^/E_`(OA!J'AFPEE'F:IXOMVM(XP3]
M\1MB60]P`B_6OZ%Q:VHY^S(/?:*>B1K]Q0/H*RAD-.3_`'TW+\#JJ^*^,I4>
M3`86%%]UJ_R1\:?L`?\`!'OX'_L<S1>/?%$B>+/&;H2VL7EOMCM&)Y\B+)"'
MI\YR_7D9Q7V(EO#$5PN-OW0O0?\`UO:K-&!Z5[5"A2PT.6FK'YGF.8XW-L4\
M1BIN4GW&1$%V.#FGT45L<*OU"FR@8IU%#U&8'C?P%X/^(_AC4/!GC?P];:GI
M>JVCVVH6-W'NCGB9<,K#W'\AZ"OYFOVY?V/_`!)^QC^UAKGP.DTZ]GTVWNQ>
M>';R2$L;G3Y6_=/N'#$$,C8_BC<=J_J$K%U/P+X8UJZ2^U?P[8W<T8`66ZM(
MW90#D`%E)`!YZUO1Q$Z4)P>JDK'D9AE%''XJAB&[3I24D_1IV_`^?_\`@DU^
MS8/V:_V+_"_AG5;'R-8UBT36-:3;AH[BX42&-CU)0;4_X#7TP%7`VC&.E-@M
MX[<;8T"C:``HP`!^E25S0A&G%1BM$>_B\35QF)E7J.[D[A45P@DPA8C@]#4M
M%4CF:NK'F'[1G[,_PA_:?^'UQ\.?C%X4M]4L)GS&\HQ+;R8XDC<?-&XSU!%?
MDU^UC_P0.^/_`,-+NY\0_LZ:I!XVT/K;Z;,1;W]NN?NX/[N<#KD,I_V:_;2D
M*J1@@8KBQ&7X3$ZSCKW/I.'^*\[X;FOJE3W>SU1_,QJGPI_;!_9TU/S+KP%X
M_P#!TT1^:[BL[RT!9>X:,!6QG@ACU]Z74?BC^V-\5T7PYJOQ!^)'B,,/EL[C
M4;Z\WCV3<W'UK^F-K:V/WX%/U44GV6S_`.?9/^^17F/(FG[M5I?UYGW7_$5%
M/WJN`IREU??\#^>#X$?\$H/VY/CYJ$$>F_!O4/#-C+(%?4?%MLUC'$IZML;;
M(YQQQ&"217ZF?\$__P#@CE\$OV2;F/Q]XVF3QAXU3:T.LWUIMCL&P0?LT9)V
M'G`<_/@<;<MG[75$7[J`?04M=F'RC"4-6KONSYK/?$#/\\INDY*%/^6)!;VU
MO;1".`;5'``Z?E4_2BBO3C%15D?#W;>HV3&0:YOXD_"GX=?%SPK=^"OB/X3L
MM8TR^C*7=E?0B1)![@]QP01R"`1S7344G%2T94)SI34H.S74_(O]KO\`X-[_
M`!#9WESXR_9#\8136S?O/^$7UN8J\1SR(K@@[AC^%P#Q]ZOA;XD_L6_MA?!&
M_E?QY\`O&&GFW8@:A#H\TUNI_O":$.I'_`OP%?TNX'3%->*)_OQ!OJ*\G$9)
MA*KYH>Z^Z/TC*/%'/\OHJCB%&M#M)'\QFD_%K]J3PY:C3='^(_CZQC0;?)AU
M>]C"^N!N&.:U;#X._MD?&B8QVOPQ^)/B8L=I^T:9?W<:G_>9"J_F/J*_I;-I
M:DY-JG_?(I5MX0<^2@^@K".223LZK:_KS/0GXI1M>E@*<9=]_P!#\&O@%_P1
M'_;M^*6L6-]XO\*67@[3@Z.USKMVIE`W9P((BYS]6'45^Z/@O2I-#\*:?HT\
M@D>SM5@=U7`8H-N0,G@XK7"*.BTM>GA,%1P<7[/=GQ'$G$^9\45XU,6U[NR6
MR*TI/EG`].OU%?D/_P`%O?V2OVD?C=^UE8>*_A+\%_$/B'38?"T%N]]I5B98
MQ(LDA*G'0C(K]@::T:-U4?E58K"PQ=+DEL<_#N>8CAS,UC:"3DE97V/YP++]
M@']O[3H?*T_]G+Q[!&7W;(=.D52V",X!QG!Q4G_#`_\`P42_Z-Z^(G_@'/\`
MXU_1T(8\8VC\J=L3^Z/RKSO[$I6MS,^YGXK9K4FYRP]-M^1_.&/V"/\`@HCG
M`_9Z^(F3_P!.<_\`C7H'[*_[%/[>/AC]H_P+X@\4?`OQY!I]EXNL)M0FN[:5
M(X84F4L[DGE0"3@^M?OYM7^Z/RH"J.0HS]*=/):,)\W,SEQ?B7F&,P\Z4L/3
M7,K:)B1;O+7=UQS7R]_P6&^%WQ`^,7[#/B;P)\,_#%]K.K74UJ;?3M.BWS2[
M9T)(!],5]1TA4-PPS7K5*<:E-P>S/@<!C*F7XVGB8*[@T]?(_$__`()"?L7_
M`+5?PH_;L\+>/_B5\"?$/A_1[.WU`W.I:E8&*./?93(J%B2"2S?I7[8CD9I!
M'&#D(/RI:PP>#I8*ER0/2XBX@Q7$F/\`K5>*3LEIY!1THHKK/!/C?_@KW^P?
MI_[7?[/5SXG\'Z,)/''A6)KWP^PCR]TN1YEJ<`L0R[MH'\6/4U^*<G[)_P"U
M(C%&_9F\?'$;Y)\(WI.-I&,"'&2<<YQS7].;*K#:PX-,-K!G/DK^0KR<;E-'
M%U543LS[SAGC[,N',#+"QCSQ>UW:WX,_//\`9Q\#>.=,_9Y\!Z;JO@S4[6ZM
M_!FEQ7-M-8S*\,BVD09&!3@@@@CVHK]#?(C_`.>:T5V+#V6YXLN(:LI-\N_G
M_P``?11174?.A1110`4'/8T44`%%%%`!1110`4'/8T44`%&`.@HHH`****`"
MBBB@`HHHH`***3<OJ*`%HI-R_P!X?G2Y![T`%%(&4C(8$#KS070=6'YT`+10
M"",@T9'7(H`,9ZT8'H*,CUI-RGHP_.@!:*3<O]X?G1N7.,B@!:*3<IZ,/SH#
MH1D,/SH`4G!Q14<LP4A4(^8'!S]/\:YKPW\7OAQXT\4:UX(\(^.],U+6/#LB
M1:[IEE>(\]@[J&02H,LA*LK#(Y!!H%=7L=311D>M(64=6'YT#%HI`RGH11N4
M]"*`%Z=336=AP!S7#?%']H/X:?"KQYX/^%_BOQ&MKKOCNZN[?PO8^6S->RVT
M0FE4$`@;4(//K796SF2!2\VXG^+UJDNIE[:/.X+5HLT4A91U8?G1O3&=PQZY
MJ346BD#*>C#\Z-Z8SN'YT`+12!E/1A^=&Y<9W#'UH`6BDWH>CC\Z-Z9QN'YT
M`+12;E_O#\ZR?'7CCPK\.O!^I>._&?B*STK2-(M7NM3U.^N%C@M84&7DD=CA
M55<DD]!0)M(UZ*R/!7BK1O&WANR\8>'-=M=1TS5+.*[TN^LYA)%<VTB[XID8
M<,KHRL".""*UBZ#JP_.@=Q#(<<+0C,V<C%<[\2/B+X:^%?@/5OB1XVU5;'1]
M#L7O-4O&1F$$$8W.Y"@DX`)Z4[X6_$+PS\5/`>D?$OP9K27^B^(=*M=2T>]4
M8%Q;3PK+%(`><,CJ>?6G;0RC6C*5D=%11UZ44C4****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****``G`S7FW[5OQ9U?X$_LZ>-OC-H6E6
M]]>>&O#EUJ5M9W3E8IVAC+A&*@D`XQD#//%>DDX&:\7_`&^O#^K>,?V+?B;X
M;T31YKZ[OO!.HPVMG;1EY)I&@8*B@<DD\"KI_$<V,E4CAI<FY\P^$/\`@I[^
MUSID'PD^+/Q>_9I\.Z7\-?BWKVGZ/I-W8^())=5M9;P@6\\L6S9Y4A(88.0"
M-V#77?%?]OO]J'Q'\3?B1X:_9(^!_AC7]!^$05/%FI^)==GM)M1NQ`)Y;6QC
MAB<.Z+E29"HW+@9R,^?_`!I^$OQ,U7]@3]COP58_#_5I]2T#Q/\`#>3Q#906
M3F>PCMHK47#2#^'84;=GICWKS7Q7^SY\*O@1^V+\7YOVNOV<?B+XDT+QWXE?
M7?!?B/P1;ZA<P7,=RBF>QEBLG!617WC,@P0N00#7=%4'&[6I\Q4JYG":I\[M
MIJ?2_P`!O^"E;?&SX^^%?`UOX8M[#PIXZ^%!\9>'-7N7Q<&2.=X[JQ<#Y&,>
MS>6X)!SDCFN9_9I_X*RW?QL^%/QP^)_C+X;6NA#X6Z5-K7AZW^U28UG3"MY]
MFF(8*0TCV94@9'S+SS7FW[>/P.\5?"S]G7X)_'C]CK]G_7[6_P#"$%_IEEX-
M%FSWUGI^KZ?-`Z2H22IC+ACR=K`'M7(_M??L8?&7P!=_!WX(_![P%J.I:-\2
M?AIHOPZ^(>J65H673HK&^L9&OK@C&&9))\D]2CU2AAIZ)&=;&9I1::;?+OYW
MT_4_2+]E[XG>,/BO^SAX/^*_Q!\-6^BZQXBT"'4KW2;:1G2T,J^8L>6Y)"LH
M/;.<<8KXQUO_`(*I?M::G\"?%W[;/PQ_9J\-:A\'M"N+RWTR6[\1W$>LWPAE
M,"WX@2(QBV\TC<N\2!%=@IP,_>FG^%].LO!<'A2RC:"UM[!;6**,XV1JH50#
M[`"OR8UCXH?%+]FK_@E5\2/^">OC[]G;QB?&/A_0=7L?[:BT9O[%N-&:220Z
MC]K!V(/(\TA"=Y=57&6%<]",.=QM<]#,\3BZ$(N+LN1M^NECZQUK_@H%\?OB
M!KGP]^$/[,/PH\/ZEX\\7?#2T\:>(3XIU6>WTK0[6>.,JC/`DDDCO(S(H"X`
M`)/S'''>//\`@K)\3O#?[..E?%*R^`T5QXXM_C%%\/O&/@Q-2^2VO"MR2;6?
MCS-S11;=X"CS""/ES7AOB#X`:+X;\=?!G]ICXT?!;Q?XJ^&WB3X!Z#HU_?>#
MOM4EUH=_!;V\D3S0VDBRF-T.,@,!@]#7:?&3X"_#K6/V7?ASJ7[)_P"S1XQT
M'2K_`/:8\.:IJ5AK>FW*7URD,DBRW\D<[,\</)^9N2`#WKHY</\`RGGTL3FD
MZ#DY/9?BD>[_``B_;Q_:!\*_M(W_`.S-^VG\(/#?AW4#X%F\7Z+JOA+6IKZT
M^PPR%)HI6E1&\Y-K$X&"!P37$Z;_`,%3_P!H>/P'H_[7WB/]G[0;?X&:YXC3
M3K6ZCUV=_$$%G)<-`FH2V_E^3Y)9<E1(7`(XXKH?VH/@CXX^)_\`P4L\+R:=
MX=OQHM]\!/$&D7.MQV[-;6]S/-B-'<<*Q5V('<"OF+]E[]GK]F[P/\/-#_9E
M_:G_`&*?BE??$#2-8.FWB65GJ,VEZB/M6([])5E-NL)3:YR01M)P,XJ.3#\M
M^4*N(S2%54U)\J/JC3_V_?VF_B+^WEXR_9#^"_P"T*_TSP1?Z8^L^++_`%AH
MHH=/N+>":0A=OSW&Z8A(QD%5R3UIW[2W[87[=_[-.F^(_CSXJ_9T\$2?"OPO
MJ8BNXH?%<QUV:P,R1"]2(0^0,EP?*,@;@\=*O_L9_#7Q?X7_`&^_VF?$NI>#
MKZRTS5=5\.G1M0N[)TAO%BTN)',3GB0*?EX/!X[5^?GCOX+:YXT_9+\>>$_C
M)^R!\1?&'[2UW?7LVH^(M4TJXGMM/@%R6\^UN`P@6`0*^R*/<Q9P,<TH1IR>
MBL5B,3CZ.'2DVY-MJWE:Q]6?M%_'#]MK5O\`@I)\(=&^#&E^%IM!UCPEJ&H^
M'-'U3Q-=V]OJ-N4MVFN+Q(X2$EB#GRE4LK<[MN!GJ_"W[9WPR^!/BK]I_P"*
MWC#X+Z)H=Q\.-3L$U[4O#Z[;SQ'</9(T8E<]6W/Y:GC@@G'-87Q^U#QO\"?V
MI_V:/VC==^%?BC6?#.B?#V_T37;C0-)>]EL;NXBM1'YL48WKN.<G&/E/3!KA
M?BO^R-\9?VEO#/[9?A+P_P"!]5M+OQ;XIT?4_"'VZW-NFI&VL[>7RXV?`))C
M*'/`8@$YSB^6F]'L<].MF$-8MN5V]?-(]AT#]OS]L#X:^+/AW<_MA_L_^%O#
MOA#XI:I!I^C:EX:\0375WHEU/&9+>"_CEB107PJEHRVW=ZC%8&L?\%%/VZ_%
MOB_XRZ+\#_V9?"&I:9\&O$E[;ZKJ&N^)9H3J-I"C2Q)`JQMFX*([,"0JYC&<
ML0.8^,WQ8^(?_!1[5_@W\"?#'[-_CGPS=>'O&]AX@^(6I>)/#TEE:Z.;*-_,
MA623_6NSEU7`P0%]:](_9)^''C_0]6_;!D\0^!-4LEU_X@:C<:+Y]FRKJ,#:
M<$26`GAPQ&,CO4N-!0YFM3H]MF$L0J<)/EL^C['TS^R3\>=/_:@_9P\'_'S2
M--DLX?%&B1WOV.4@M;NV0\9(X.U@RY]N:^5[']OO]N?XJ_$3XL>`/V?_`-G/
MP??K\(/$<]GJ5_KVOSVJZC$D:R)'`J(S?:'7S#\V$&U<D;A7L7_!)+PGXM\"
M?\$[OA=X4\<^&[O2=6LO#S+?Z=?PF.:"3[1*=KJ>AP17R/\`L^_M<:Q^R_\`
MM%?M26^H?!#QGXGMM2^)4SZ)/X5T-[U9-26V5!:3;,F$LAMR&?"D`\]JQIQC
M-O0Z\;B<33I8=.5F[I_)7_0C_:F_:^UO]HCQM^QC^TO\%OAT^HZUJVN>)$L?
M#%Y>B%4U!K.*V>&63;\L:2,Q9QSM7(SFOIC]EC]L?X]_$?XL_$O]FO\`:$^#
M^C:5X\^'VE6FIP?\(OK$EQI^JV]S&S0;'E17C<L-IR,8)]#7S1\#?V4_C5\)
M=3_8KLO$/@'4GO+#Q5XLUOQ8D%NTB:+]NM%,,<[KD1\,%(_O`@?=KN/CI\./
MVF(?VM/VI_&WP-\*ZI:ZSJ7P=T*V\'ZK%$8X[J[C23='#*QP74%OH371RTI1
M47H>;AZF84Y2KR;=[-KOHCNH?VV?VTOA!\5O`NA?M<_`WP3I7AGXB^(H]#TZ
M3PCXGN+V^TJ]E1C"EPLT4<<BEL`M&Q"@D\D8J+X;?M[_`+4'QI_:H^(7P/\`
MAO\`L_:'+X;^&/BUK+Q1XIO]99-MF8FV>7%M!>Y9HY<JO[M5VG.6%?'V@_!S
MX<Z[XE^`.N?`/]C;XAVGBG0_B'HDWQ+\<^)M!NUE649,T,DLQ)FS(9&+H"BX
M&6[5]H_L$_#_`,9^'/BK^U1?Z_X5O[*+6_BO-=Z//=V;QB\A^QJN^+<!YB[@
M>1D<\43A14;HJAB\TK34+M+5_@>-M_P5[_:\T;]FNT_;;\3?LR>&D^&EIK\N
MD:Z++Q+(VHRRB_:T$UM$Z!#&"%7#DL9-W`0`U[?\$OVU/VI8?VLM'_9C_:S^
M"'AOPZWC+PU=:YX2O/#NO27GDI;X\VVN]Z*!*H.=R%E.>O6OF3Q#\$OC5)_P
M0M@^&D'PKU]_$8^)4ER=#DT]UNC&/%$DN_RR,[/+^<>JX/>OI#]H_P``?%+4
M?^"H7PG\;^"_"UW+:V'PO\3PMJWD'[);7DB)Y"2/T5F(/<<"L^6FUL5"690J
M<RE)VL_\RM\>OVT_VX?V9K6_^.7Q2_9U\#I\+=-\0I8W4-AXNN)-<%C)=BWB
MO!#Y(@((9&\OS-PY&*VOC1^W9\;?$/[0,?[)?[%?PAT;Q+XKL_#D&O\`B?5?
M%>JR66EZ59SL!#&[1(\C3N"K!`I`4Y-?GI\0/@O_`,)I^R?K?A_Q?^Q]\3O$
M?[1;:_\`:/$OBW6-'NIA8!=15EFMYW9HI(O*\M5CC#'[Y[5]9)>>/?\`@G_^
MW1XJ_:5\7?!7Q9XE\`?%;P1H5K<ZKX4TA[^?1=4TZUCMQ!+;1YD"R(I.X#`;
M@T_94K:J[*CF&-E5:;:AUT9Z?\1?VR_VI=)\>>#/V4?`7P<\&W'QFU?PK+KW
MBR'4?$-PFB:'9).\*2>=%$TTOF/'M0>6#ZXKF)/^"IWCA?@=%XKU;X1V%GXS
MT'XT6?P[\<Z%/J+O;6MS)<I%+-;RJNZ1=C;TW`9#<UY/^UKX-T3XC?M=^"OV
MY/BI^S?\1=0^&GB/X<?V+J=CIVGW<>JZ#>PWD\MO+<6MLZS;)4E(P`<9.<8Y
ML_'3X#^"6_83E^)'[&/[*WC73(=-^+>D>)]7\/:S9W":KK26<J;[E(;AFD9F
M7;C=AB%SCBFHPY5H$\5F-6O/EDTHZ)6W1]0_'#]JCXJ^`/VP/"?[*W@#P3HF
MI77BWP'J^MV-]JM])"L=Y:AO)B<(C8B=L*[CYE!!56YKY+_9,^-G[5&I_LZ_
MM0>*_P!H/P)X0\6^#=$\6^*CK=AJVOW-TWVZ*SM"=*CB:%5.GB/;A\A\R-\O
M6N]\%?%KQS^UA_P59^&'QU\-_L^^-]!\$Z+\/M9TZ+7O$^@R62W%PZ[W4H_S
M1@$JJEAASG'3GCOAA<>-O!?P0_;`_9(UWX,^,$\3>)O%'B_Q-H<Z>'9GL;RR
MGL;.*$17`'ER2NR,1$#NQ@TDE&/F35K8K%8KVG,U'7H]=$>O']O#QCX2^$WP
M`^#G[,OP#T?4_B%\4OASINKZ)X8>^-GH_AS3?L,#DRS*&811[]B!$8L(\<<9
M],U3X@_\%#=/^"MI))\#_AZ_Q*N/$OV2\@/BV=-&MM-$#-]O,WE><V'V1^4$
M#$L3C'-?+]MX"^,O[*VM_LN_MEO\(_$'B31?#_[/VE^$?'VCZ#IYEU#1]MI`
MPN/L_P!]U#/*KHHW`QCVJ[^W!\:=4_:GC^%7Q*UGX)?%1?@A;^*;Z'QWHUKH
M=S::A/(ENAM+F:WC(G:V+NPP.I!SVPO9Q;1M#&XF$)NIS<VR7D=?\1_VN/B?
M\6_V<?VD_P!F[]H;P+I'AWQ_X`\!7$VHGPWJ4MWIUY:W-DSQ3P22HDF,-R'4
M$$CBL_X6_MB_&SP%\$?V8_V1?V:OA_X8U3QEXB^`6B:W)?>-=:FLM.M+2+3;
M=`H:WBDD>1FC?Y0O``)X.:\:^$/P,U73=4_:OO?@K^REXA\"^%_%/PFAC\%Z
M'?:4T)NI1;R(2J'+*\A4-Y3-N7<<@<"N]^+F@_`1OV-_@5\,/VF_V7?B?>^)
M=$^#>A'PUXL\#^'KEK_2-22RAC-JL]N=]K.LL:MA_DYYS@UHHTO::ZHY(5<?
M*G*I=IVM_P"37_(^P_#_`,0?VMY-!L7\3?#7P=#J36<1U"&V\3RF..?8/,5"
M8P2H;(!(!Q17YL^#O"7_``<+IX1TI=$U"Y2R&FP"T36FMS>+%Y:[!.>\N,;S
M_>S14<L/([EBZ]OAD?L[1117`?6!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!UJ(V\3Q>6PRO3%%%-;">KL)]AM!\OD@9.>">M*UI:]XA
M[9S111=DN,>Q$NGV:*$6+`'0`GU)_J:!I]L/F6(##$_B22?U)HHIINXDHW>@
MZ*&*)2B,>1T-?&OQ._X)N_M5?&G1;_X6?%W_`(*+:MJOP[U6_+ZGX?M_`EO;
M:C=6ADWBS;4$N,[,[02(02N5/#&BBE&<J<W8PKT:>)BO:'UEX'\#>'_!/A33
MO!F@V*0:?I%A#96$"<"*&-%15&.@"JH_"MDVENRX>,'%%%)U)-W-H4:=-<D5
MH(MG&K;RO3/\1[T?8+,\B(`8P0!@8HHI<\F:.$)*[0"UMUX2+`[`'ITZ>G2D
M.FVC@CR5.3GG/!XZ>G04455W8AJ-]@%A;])DSSD4W^R[=/\`CVB"#'&TD>_\
M^?K112&FD[V'FR4X)B3(Z''.?6E%HI.77H<\$CVHHHV&K-;$@ACC38!@5XC^
MR_\`LC']GCQU\4?&-QX]763\2O&S^('M5TK[.-/S`D7V<-YK>;C8#OPG^Z**
M*N#:V,YT*56I'F6U[?<>S6]I:I\B*=JD8&3@8_\`U4XZ?:[1OBW8/R[F)Q^=
M%%2[MIC48I-6&#2K/<&\A<C(!QV[CW'M3O[/@C&$C"\8&***$W<;C%IZ"?9(
M3(%=<@CD9IXLHP,.I(R>K$]\T44YR:*BEM;H-DTNRE7;Y([G()&,C%$-A"A)
M,8;.?O#/?..>WM114J3>HG&$79)"C3;$'>;=0?8>Y/\`4TOV"W4Y6-0I;)&.
M"?7ZT44<S;L%HQ=TMR.32-/D7`@52>ZY!QV&1Z9X].U.&F6`D,OE`L0.I/&,
MX(]#SU'/3T%%%.[1,8Q:6FPOV"W(PB`=.A-,;1[)^MJ@YZJ,>OI]2?KS1123
M=BI*-]@@TC3H)"\=L/F.<$Y`X`X!X`X'`^O4U))I]F>L"],9'!_.BBEJM;A&
9$+6L1MI6G,Q9K-"2<DD4445%V5RQ['__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
